Preface
Introduction to special issue on biomarker-based clinical trial designs in oncology
Chinese Clinical Oncology
2015;
4
(3)
:28
.
(25 September 2015)
Review Article
Statistical principles for omics-based clinical trials
Chinese Clinical Oncology
2015;
4
(3)
:29
.
(25 September 2015)
Molecular and clinical implementations of ovarian cancer mouse avatar models
Chinese Clinical Oncology
2015;
4
(3)
:30
.
(25 September 2015)
An overview of the NCI precision medicine trials—NCI MATCH and MPACT
Chinese Clinical Oncology
2015;
4
(3)
:31
.
(25 September 2015)
Design and statistical principles of the SHIVA trial
Chinese Clinical Oncology
2015;
4
(3)
:32
.
(25 September 2015)
An overview of the design and conduct of the BATTLE trials
Chinese Clinical Oncology
2015;
4
(3)
:33
.
(25 September 2015)
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2− invasive breast cancer
Chinese Clinical Oncology
2015;
4
(3)
:34
.
(25 September 2015)
The FOCUS4 design for biomarker stratified trials
Chinese Clinical Oncology
2015;
4
(3)
:35
.
(25 September 2015)
Lung-MAP—framework, overview, and design principles
Chinese Clinical Oncology
2015;
4
(3)
:36
.
(25 September 2015)
Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials
Chinese Clinical Oncology
2015;
4
(3)
:37
.
(25 September 2015)
Biomarker-based trials in neuro-oncology
Chinese Clinical Oncology
2015;
4
(3)
:38
.
(25 September 2015)
Disclosure:
The supplement “Clinical Trials in the Genome Era—Study Designs and Endpoints, Practical Considerations” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Daniel Sargent, Sumithra Mandrekar and Axel Grothey served as the unpaid Guest Editors for the supplement.